发明公开
- 专利标题: 1-NAPHTHYL ALKYLPIPERIDINE DERIVATIVE
- 专利标题(中): 1-萘基烷基哌啶衍生物
-
申请号: EP07829299.2申请日: 2007-10-05
-
公开(公告)号: EP2098509A1公开(公告)日: 2009-09-09
- 发明人: SEKIGUCHI, Yoshinori , KANUMA, Kosuke , SAKAGAMI, Kazunari , HAYASHI, Masato , KASHIWA, Shuhei , OMODERA, Katsunori
- 申请人: Taisho Pharmaceutical Co. Ltd.
- 申请人地址: 24-1 Takata 3-chome Toshima-ku Tokyo 170-8633 JP
- 专利权人: Taisho Pharmaceutical Co. Ltd.
- 当前专利权人: Taisho Pharmaceutical Co. Ltd.
- 当前专利权人地址: 24-1 Takata 3-chome Toshima-ku Tokyo 170-8633 JP
- 代理机构: HOFFMANN EITLE
- 优先权: JP2006275227 20061006; JP2007151270 20070607
- 国际公布: WO2008044632 20080417
- 主分类号: C07D211/58
- IPC分类号: C07D211/58 ; A61K31/4468 ; A61K31/453 ; A61K31/454 ; A61K31/4545 ; A61K31/496 ; A61K31/506 ; A61K31/5377 ; A61P3/04 ; A61P3/06 ; A61P3/10 ; A61P9/10 ; A61P9/12 ; A61P25/08 ; A61P25/14 ; A61P25/18 ; A61P25/20 ; A61P25/22 ; A61P25/24 ; A61P25/28
摘要:
Disclosed is a pharmaceutical composition comprising a compound represented by the formula (I)
or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.
or a pharmaceutically acceptable salt thereof as an active ingredient, which has an antagonistic activity on a melanin-concentrating hormone receptor. The pharmaceutical composition is useful, due to its antagonistic activity on a MCH receptor, for the prevention or treatment of a disease such as depression, anxiety disorders (e.g., generalized anxiety disorder, post traumatic stress disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder), attention deficit disorder, mania, manic-depressive disorder, schizophrenia, mood disorders, stress, sleep disorder, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, a cardiovascular diseases, hypertension, dyslipidemia, cardiac infarction, movement disorder (e.g., Parkinson's disease, epilepsy, convulsion, tremor), drug abuse and drug addiction.
信息查询